Reuters logo
BRIEF-Prometic receives FDA clearance of its IND to initiate PBI-4050 phase 2/3 trial in patients with idiopathic pulmonary fibrosis
September 25, 2017 / 10:45 AM / in a month

BRIEF-Prometic receives FDA clearance of its IND to initiate PBI-4050 phase 2/3 trial in patients with idiopathic pulmonary fibrosis

Sept 25 (Reuters) - Prometic Life Sciences Inc

* Prometic receives FDA clearance of its IND to initiate pivotal PBI-4050 phase 2/3 trial in patients with idiopathic pulmonary fibrosis

* Prometic Life Sciences Inc - ‍Prometic plans to supplement IND with a protocol for a study of PBI-4050 monotherapy in IPF patients in October 2017​

* Prometic Life Sciences Inc - ‍U.S. IND to be followed by clinical trial applications in Canada, Europe, Australia and Japan throughout Q4 2017​

* Prometic Life Sciences- ‍Phase 3 stage would randomize an additional up to 450 subjects to receive nintedanib plus either placebo or chosen PBI-4050 dose​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below